![]() |
Name |
Daldiniol C
|
Molecular Formula | C13H16O3 | |
IUPAC Name* |
4-[5-(hydroxymethyl)-2-methoxyphenyl]-2-methylbut-3-yn-1-ol
|
|
SMILES |
COc1ccc(CO)cc1C#CC(C)CO
|
|
InChI |
InChI=1S/C13H16O3/c1-10(8-14)3-5-12-7-11(9-15)4-6-13(12)16-2/h4,6-7,10,14-15H,8-9H2,1-2H3/t10-/m0/s1
|
|
InChIKey |
ZRHJKVVIKGFPAV-JTQLQIEISA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 220.27 | ALogp: | 1.2 |
HBD: | 2 | HBA: | 3 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 49.7 | Aromatic Rings: | 1 |
Heavy Atoms: | 16 | QED Weighted: | 0.761 |
Caco-2 Permeability: | -4.229 | MDCK Permeability: | 0.00001970 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.009 | 20% Bioavailability (F20%): | 0.003 |
30% Bioavailability (F30%): | 0.014 |
Blood-Brain-Barrier Penetration (BBB): | 0.982 | Plasma Protein Binding (PPB): | 83.77% |
Volume Distribution (VD): | 0.985 | Fu: | 7.10% |
CYP1A2-inhibitor: | 0.519 | CYP1A2-substrate: | 0.826 |
CYP2C19-inhibitor: | 0.683 | CYP2C19-substrate: | 0.787 |
CYP2C9-inhibitor: | 0.409 | CYP2C9-substrate: | 0.793 |
CYP2D6-inhibitor: | 0.044 | CYP2D6-substrate: | 0.874 |
CYP3A4-inhibitor: | 0.289 | CYP3A4-substrate: | 0.482 |
Clearance (CL): | 10.246 | Half-life (T1/2): | 0.804 |
hERG Blockers: | 0.007 | Human Hepatotoxicity (H-HT): | 0.266 |
Drug-inuced Liver Injury (DILI): | 0.919 | AMES Toxicity: | 0.538 |
Rat Oral Acute Toxicity: | 0.138 | Maximum Recommended Daily Dose: | 0.134 |
Skin Sensitization: | 0.59 | Carcinogencity: | 0.806 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.807 |
Respiratory Toxicity: | 0.502 |